10:12 AM EST - Theratechnologies Inc. : Announced that new positive results about its two investigational peptide-drug conjugates TH1902 and TH1904 will be presented tomorrow during an oral presentation at a virtual session of the Annual Meeting of the American Association for Cancer Research. Data from the oral presentation “Increasing potency of anticancer drugs through Sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer,” show that both TH1902 (docetaxel peptide conjugate) and TH1904 (doxorubicin peptide conjugate), two unique Sortilin positive (SORT1+) targeting investigational PDCs, are more effective and better tolerated in animal models than two commonly-used ovarian cancer treatments. Theratechnologies Inc.
shares T.TH are trading down $0.03 at $3.76.
